Other substances

CC12.1

An anti-SARS-CoV-2 monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

CC12.1 is an antibody found in patients who have recovered from wild-type SARS-CoV-2 infection (Rogers et al., 2020). The Delta variant's two mutations, L452 and T478, are situated distant from the CC12.1 epitope on the receptor binding domain (RBD). As a result, they do not impact the interaction between the RBD and CC12.1 (Patrick et al., 2022).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain
Spike protein Spike variant Protein factor In vitro Antibody 		Expi293 HEK cells

CC12.1 is expected to be capable of neutralizing the Delta variant. 

 Jul/15/2022

AI-suggested references

Link Publication date
Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
Mar/01/2022
Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design.
Mar/23/2021
Export (.csv)